With the big American Society of Clinical Oncology meeting coming up in two weeks, anticipation about the coming onslaught of data is mounting. Last night, ASCO released some key abstracts for studies to be presented at the meeting, offering an aperitif to oncology-drug followers. Here is a sampling of news, some from our sister publication FierceBiotech.
Bristol-Myers Squibb will collaborate with Adaptive Biotechnologies to develop immunological biomarkers for cancer, representing another step forward in the development of personalized medicine.
Massachusetts General Hospital researchers repurposed a portable, fast-acting diagnostic device they developed to spot cancer as a successful test for tuberculosis and other infectious diseases such as pneumonia. Additionally, they used it to pinpoint antibiotic resistant bacteria such as the deadly MRSA.
Delcath Systems' cancer-drug delivery device suffered a hitch as the FDA said the associated risks likely outweigh any benefit.
In a novel deal, U.K. CRO Ergomed has hitched up with Cel-Sci for a Phase III trial of its head and neck cancer drug, but instead of just handling the study, Ergomed is putting up $30 million to fund development in exchange for single-digit royalties from the treatment.
AstraZeneca and Bind Therapeutics have joined forces in the creation of a kinase inhibitor nanotech for treating cancer, part of Bind's Accurin line of delivery platforms.
Could Australia's success with HPV vaccination help boost similar efforts in the U.S.? If hard numbers on results could help, then yes. A BMJ study shows that immunizing young women against the human papillomavirus has already proven its worth.
Drug delivery vehicles on the nano scale often rely on passive diffusion to get drugs to their target. But researchers at the University of San Diego are taking a more active approach, with self-propelled "microrockets" that could enhance drug delivery for cancer.
In a study trialed by the University of Pennsylvania, researchers have developed a vaccine using trial participants' own blood and tumor cells.
San Diego-based Ambrx welcomed an influx of cash for the further development of its drug-delivery technology: antibody drug conjugates, or ADCs.